ESMO I-O 2019: Overall Survival With Nivolumab/Ipilimumab in Lung Cancer
Posted: Thursday, December 19, 2019
Based on the overall survival analysis of CheckMate 817, a treatment of flat-dose nivolumab plus ipilimumab in patients with advanced non–small cell lung cancer (NSCLC) with and without a poor performance status had “durable” outcomes. These study findings were presented at the European Society for Medical Oncology (ESMO) Immuno-Oncology Congress 2019 in Geneva by Fabrice Barlesi, MD, PhD, of the Aix-Marseille Université, and colleagues (Abstract 92O).
A total of 589 patients with previously untreated stage IV or recurrent NSCLC were enrolled in the multicohort, single-arm, phase IIIb study. Cohort A (n = 391) contained patients with an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, whereas cohort A1 (special populations, n = 198) had an ECOG performance status of 2 or a specified comorbidity such as HIV or renal impairment. Patients received nivolumab at 240 mg every 2 weeks plus low-dose ipilimumab at 1 mg/kg every 6 weeks for up to 2 years or until disease progression.
In cohorts A and A1, the median overall survival was 17.0 months and 9.9 months, with a minimum follow-up of 21 months and 14 months, respectively. After 1 year, overall survival was 60% for cohort A and 47% for cohort A1. The cohorts had a similar safety profile, with comparable rates of treatment-related adverse events. Additionally, the median time range to onset of adverse events was similar (cohort A, 2–26 weeks;cohort A1, 2–21 weeks).
Overall survival outcomes in cohort A were similar to those in CheckMate 227, but comorbidities affected survival for patients in cohort A1.
Disclosure: The study authors’ disclosure information can be found at oncologypro.esmo.org.
